MX2009005750A - 2-{[2-(substituted amino)ethyl]sulfonyl}ethyl n,n,n',n'-tetrakis(2 -chloroethyl)phosphorodiamidates. - Google Patents

2-{[2-(substituted amino)ethyl]sulfonyl}ethyl n,n,n',n'-tetrakis(2 -chloroethyl)phosphorodiamidates.

Info

Publication number
MX2009005750A
MX2009005750A MX2009005750A MX2009005750A MX2009005750A MX 2009005750 A MX2009005750 A MX 2009005750A MX 2009005750 A MX2009005750 A MX 2009005750A MX 2009005750 A MX2009005750 A MX 2009005750A MX 2009005750 A MX2009005750 A MX 2009005750A
Authority
MX
Mexico
Prior art keywords
ethyl
phosphorodiamidates
chloroethyl
tetrakis
sulfonyl
Prior art date
Application number
MX2009005750A
Other languages
Spanish (es)
Inventor
Wenli Ma
Kevin T Weber
Robert M Yee
Original Assignee
Telik Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Telik Inc filed Critical Telik Inc
Publication of MX2009005750A publication Critical patent/MX2009005750A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/24—Esteramides
    • C07F9/2404—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/2408—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic of hydroxyalkyl compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/59—Hydrogenated pyridine rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

2-{[2-(Substituted amino)ethyl]sulfonyl}ethyl N,N,N',N' -tetrakis(2-chloroethyl)-phosphorodiamidates, their preparation and intermediates in their preparation, pharmaceutical compositions containing them, and methods of treatment using them. The compounds are useful for treating cancer, alone and in combination with other anticancer therapies (I).
MX2009005750A 2006-11-29 2006-11-29 2-{[2-(substituted amino)ethyl]sulfonyl}ethyl n,n,n',n'-tetrakis(2 -chloroethyl)phosphorodiamidates. MX2009005750A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2006/045717 WO2008066526A1 (en) 2006-11-29 2006-11-29 2-{[2-(substituted amino)ethyl]sulfonyl}ethyl n,n,n',n'-tetrakis(2 -chloroethyl)phosphorodiamidates

Publications (1)

Publication Number Publication Date
MX2009005750A true MX2009005750A (en) 2009-07-14

Family

ID=38197807

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009005750A MX2009005750A (en) 2006-11-29 2006-11-29 2-{[2-(substituted amino)ethyl]sulfonyl}ethyl n,n,n',n'-tetrakis(2 -chloroethyl)phosphorodiamidates.

Country Status (7)

Country Link
EP (1) EP2097139A1 (en)
JP (1) JP2010511040A (en)
CN (1) CN101553282A (en)
AU (1) AU2006351255A1 (en)
CA (1) CA2670628A1 (en)
MX (1) MX2009005750A (en)
WO (1) WO2008066526A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10077843B2 (en) 2013-11-12 2018-09-18 Eagle Industry Co., Ltd. Division type mechanical seal

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200600091A (en) * 2004-05-21 2006-01-01 Telik Inc Sulfonylethyl phosphorodiamidates

Also Published As

Publication number Publication date
CN101553282A (en) 2009-10-07
EP2097139A1 (en) 2009-09-09
JP2010511040A (en) 2010-04-08
WO2008066526A1 (en) 2008-06-05
AU2006351255A1 (en) 2008-06-05
CA2670628A1 (en) 2008-06-05

Similar Documents

Publication Publication Date Title
GEP20125469B (en) Inhibitors of akt activity
MX2008012422A (en) Pyridyl- and pyrimidinyl-substituted pyrrole-, thiophene- and furane-derivatives as kinase inhibitors.
MY162319A (en) Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer
EA200501849A1 (en) DERIVATIVES OF PYRAZOLOHINAZOLINE: METHOD FOR OBTAINING AND USING AS KINAZ INHIBITORS
HK1136292A1 (en) Substituted pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
CY1112889T1 (en) AZETIDINE NUCLEOSIDISE AND PHOSPHORILAIL ANALOGES analogues
MX2007009649A (en) Meleimide derivatives, pharmaceutical compositions and methods for treatment of cancer.
PL2324008T3 (en) 3,4-diarylpyrazoles as protein kinase inhibitors
MX2009006742A (en) Novel compounds.
EA200970595A1 (en) DERIVATIVES OF SUBSTITUTED INDAZOLS ACTIVE AS KINAZ INHIBITORS
WO2007024717A3 (en) Agents for preventing and treating disorders involving modulation of the ryr receptors
EA201100030A1 (en) PYRAZOL COMPOUNDS 436
UA96449C2 (en) Stable laquinimod preparations
PL1778680T3 (en) Spirocyclic cyclohexane derivatives
EA200602047A1 (en) SULPHONYLETHYL PHOSPHORODYAMIDATES, INTENDED FOR USE IN CANCER TREATMENT
TW200738659A (en) Novel compounds
EA201000436A1 (en) STEROID [3,2-С] PYRAZOLIC COMPOUNDS WITH GLUCOCORTICOID ACTIVITY
TNSN07419A1 (en) Methods for treating drug resistant cancer
TW200639156A (en) New compounds
TW200635916A (en) Compounds
MX2008015775A (en) Compounds and compositions for treatment of cancer.
WO2007076087A3 (en) 3-aryl-substituted quinazolones, and uses thereof
MX2009003039A (en) Use of an anti-cd151 antibody in the treatment of cancer.
MY147634A (en) New crystalline forms
MXPA05011785A (en) Positive modulators of nicotinic acetylcholine receptors.